Compare Walt Disney Co (DIS) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Walt Disney Co vs BIO-TECHNE Corp — how do they compare? Walt Disney Co trades at $103.09 (market cap $178.16B), while BIO-TECHNE Corp trades at $72.1 (market cap $11.24B). The key difference: Walt Disney Co is far larger — about 15.9× BIO-TECHNE Corp's market cap, and Walt Disney Co pays the higher dividend (1.45%). Which is the better fit depends on your goals.
| DIS | TECH | |
|---|---|---|
Market Cap | $178.16B | $11.24B |
Volume | 7,546,013 | — |
Sector | Media | Health |
52-Week High | $118.86 | $72.29 |
52-Week Low | $92.40 | $43.31 |
Enterprise Value | $219.02B | $11.32B |
Dividend Yield | 1.45% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Disney (DIS) trades at $104.895, up 0.21% today, with a bullish technical outlook from moving averages but overbought RSI signals. The company has consistently beaten earnings estimates, with Q2 2026 EPS of $2.06 exceeding expectations. Revenue grew to $94.43B in 2025, and net income surged to $12.40B, reflecting strong operational performance. Recent news highlights advertising opportunities from major events like the Super Bowl, though regulatory challenges with the FCC and box office disappointments pose headwinds.
The outlook remains positive with a consensus price target of $126, implying 20% upside. Strengths include robust cash flow growth and analyst buy ratings at 62.5%. Risks involve regulatory disputes, content performance volatility, and high debt levels. Investors should weigh solid fundamentals against near-term sentiment pressures from overbought conditions and competitive streaming dynamics.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Walt Disney Co
The Walt Disney Company is an entertainment company with operations in media networks, park experiences & consumer products, studio entertainment and Direct-to-Consumer networks and channels. The Company serves customers worldwide.
Read more on DIS →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
